This is in line with the finding that, out of a cohort of 29 HER3+ clinical tumors, only one was responsive to the novel HER3-targeting monoclonal antibody GSK2849330, and this was the case of a CD74-NRG1-rearranged lung cancer, underlining the importance of signaling input through HER3 by this neuregulin fusion protein [84]. The gene discussed is NRG1; the disease is lung carcinoma.